(Q43855350)

English

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

scientific article published in January 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 November 2017

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). (English)

1 reference

Europe PubMed Central

27 November 2017

0 references

1 reference

based on heuristic

inferred from title

circulatory system

1 reference

based on heuristic

inferred from title

author name string

Alise S Reicin

1

1 reference

Europe PubMed Central

27 November 2017

Deborah Shapiro

2

1 reference

Europe PubMed Central

27 November 2017

Rhoda S Sperling

3

1 reference

Europe PubMed Central

27 November 2017

Eliav Barr

4

1 reference

Europe PubMed Central

27 November 2017

Qinfen Yu

5

1 reference

Europe PubMed Central

27 November 2017

language of work or name

0 references

publication date

1 January 2002

1 reference

Europe PubMed Central

27 November 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

27 November 2017

89

1 reference

Europe PubMed Central

27 November 2017

204-209

1 reference

Europe PubMed Central

27 November 2017

2

1 reference

Europe PubMed Central

27 November 2017

Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Indobufen: an updated review of its use in the management of atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902201-9

7 January 2021

Identifiers

10.1016/S0002-9149(01)02201-9

1 reference

Europe PubMed Central

27 November 2017

1 reference

Europe PubMed Central

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43855350&oldid=2103918208"